Maulin Patel1, Junad Chowdhury2, Huaqing Zhao3, Xiaoning Lu3, Stephanie Roth4, Coral X Giovacchini5, Momen M Wahidi5, Gerard Criner6. 1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Texas Health Science Center at Houston, Houston, TX. 2. Medical Critical Care Services, Inova Fairfax Medical Center, Annandale, VA. 3. Department of Biomedical Education and Data Science, Lewis Katz School of Medicine at Temple University. 4. Department of Biomedical & Research Services Librarian, Temple University. 5. Division of Pulmonary, Allergy and Critical Care Medicine, Duke University, Durham, NC. 6. Department of Thoracic Medicine, and Surgery, Temple University Hospital, Philadelphia, PA.
Abstract
BACKGROUND: Pharmacologic therapeutics for advanced emphysema have limited benefit. Bronchoscopic lung volume reduction with endobronchial valves (EBVs) have reported improvements in lung function, breathlessness, and quality of life through randomized clinical trials, with less morbidity as comparted to Surgical Lung volume Reduction. We here present a Meta-analysis and systematic review of bronchoscopic lung volume reduction in advanced chronic obstructive lung disease patients. METHODS: PubMed (NLM), Embase (Elsevier), and Web of Science (Clarivate Analytics) search was conducted using a combination of keywords and subject headings. The search was confined to the last 15 years and was completed on October 23, 2020. Only placebo-controlled randomized control trials of emphysema patients with EBV were included. Quality assessment was done by 2 independent reviewers. RESULTS: Nine studies were included for the meta-analysis with a total number of 1383 patients of whom 888 received EBV and 495 standard of care (SOC) medications. Our Metanalysis show statistically significant improvement in forced expiratory volume in first second, percentage forced expiratory volume in first second, St. George's respiratory questionnaire, and 6-minute walk distance in EBV group compared with SOC. Residual volume had statistically significant reduction after EBV placement compared with SOC. These differences continued to be present during short-term (<=6 mo) and long-term follow-up (>=6 mo). These improvements were even higher when the EBV patients'. Collateral ventilation was negative/fissure was intact (CV-/FI >90%). The rate of hemoptysis and pneumothorax was higher in the EBV group compared with SOC, however, did not lead to increased fatal outcomes. CONCLUSION: In conclusion, EBV has favorable effects on patients' outcomes in patients who have heterogeneous emphysema particularly with no collateral ventilation.
BACKGROUND: Pharmacologic therapeutics for advanced emphysema have limited benefit. Bronchoscopic lung volume reduction with endobronchial valves (EBVs) have reported improvements in lung function, breathlessness, and quality of life through randomized clinical trials, with less morbidity as comparted to Surgical Lung volume Reduction. We here present a Meta-analysis and systematic review of bronchoscopic lung volume reduction in advanced chronic obstructive lung disease patients. METHODS: PubMed (NLM), Embase (Elsevier), and Web of Science (Clarivate Analytics) search was conducted using a combination of keywords and subject headings. The search was confined to the last 15 years and was completed on October 23, 2020. Only placebo-controlled randomized control trials of emphysema patients with EBV were included. Quality assessment was done by 2 independent reviewers. RESULTS: Nine studies were included for the meta-analysis with a total number of 1383 patients of whom 888 received EBV and 495 standard of care (SOC) medications. Our Metanalysis show statistically significant improvement in forced expiratory volume in first second, percentage forced expiratory volume in first second, St. George's respiratory questionnaire, and 6-minute walk distance in EBV group compared with SOC. Residual volume had statistically significant reduction after EBV placement compared with SOC. These differences continued to be present during short-term (<=6 mo) and long-term follow-up (>=6 mo). These improvements were even higher when the EBV patients'. Collateral ventilation was negative/fissure was intact (CV-/FI >90%). The rate of hemoptysis and pneumothorax was higher in the EBV group compared with SOC, however, did not lead to increased fatal outcomes. CONCLUSION: In conclusion, EBV has favorable effects on patients' outcomes in patients who have heterogeneous emphysema particularly with no collateral ventilation.
Authors: Jonas F Kristiansen; Michael Perch; Martin Iversen; Martin Krakauer; Jann Mortensen Journal: Respiration Date: 2019-06-05 Impact factor: 3.580
Authors: Franziska C Trudzinski; Anna J Höink; Daniela Leppert; Sebastian Fähndrich; Heinrike Wilkens; Thomas P Graeter; Frank Langer; Robert Bals; Peter Minko; Philipp M Lepper Journal: Respiration Date: 2016-09-08 Impact factor: 3.580
Authors: Arschang Valipour; Felix J F Herth; Otto C Burghuber; Gerard Criner; Jean-Michel Vergnon; Jonathan Goldin; Frank Sciurba; Armin Ernst Journal: Eur Respir J Date: 2013-07-11 Impact factor: 16.671
Authors: Christian Thomsen; Dorothea Theilig; Dominik Herzog; Alexander Poellinger; Felix Doellinger; Nils Schreiter; Vera Schreiter; Dirk Schürmann; Bettina Temmesfeld-Wollbrueck; Stefan Hippenstiel; Norbert Suttorp; Ralf-Harto Hubner Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-06-09
Authors: Karin Klooster; T David Koster; Christoph Ruwwe-Glösenkamp; Dorothea Theilig; Felix Doellinger; Jacopo Saccomanno; Huib A M Kerstjens; Dirk-Jan Slebos; Ralf-Harto Hübner Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-06-09